254 results on '"Conticello C"'
Search Results
2. P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
3. P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS
4. P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
5. P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA
6. P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
7. P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
8. High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
9. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
10. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
11. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents
12. PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS-COV2 BREAKTHROUGH INFECTION
13. P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
14. P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
15. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
16. CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE VS ASCT, FOLLOWED BY MAINTENANCE WITH LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE IN NEWLY DIAGNOSED MM PATIENTS: A PHASE 3 RANDOMIZED EMN TRIAL: PH-O132
17. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma
18. CD95/CD95L interactions and their role in autoimmunity
19. BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint
20. AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS BORTEZOMIB-MELPHALAN-PREDNISONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: FINAL ANALYSIS OF THE PHASE 3 EMN02/HO95 STUDY
21. Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5)
22. Primary diffuse cutaneous plasmacytoma: when a correct clinico-pathologic approach is mandatory for patient's health. A case report
23. PF632 EARLY SALVAGE TREATMENT WITH SECOND-GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE PROLONGS OVERALL SURVIVAL: A REAL-WORLD SINGLE CENTER EXPERIENCE
24. PB2128 CLINICAL BENEFIT OF LONG-TERM DISEASE CONTROL WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
25. PB2123 FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL-LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK
26. PB2185 DARATUMUMAB MONOTHERAPY IN REAL LIFE COMMUNITY SETTING OF REFRACTORY MYELOMA PATIENTS: A RETROSPECTIVE UNICENTRIC STUDY
27. PS1362 TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO-1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN-REGULATES CD38 IN MULTIPLE MYELOMA
28. PF585 GENE-EXPRESSION PROFILE OF HIGH-DENSITY NEUTROPHILS REVEALS PROGRESSIVE DIFFERENCES IN MGUS AND MULTIPLE MYELOMA, ASSOCIATED WITH REDUCED PHAGOCYTOSIS AND INCREASED INFECTION SUSCEPTIBILITY
29. PB2189 FREE LIGHT CHAINS IN MULTIPLE MYELOMA: IS IT TIME TO EXTEND THEIR APPLICATION?
30. PS1318 LONG TERM FOLLOW‐UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE: A SINGLE CENTRE EXPERIENCE
31. PS1363 TARGETING MITOCHONDRIAL FITNESS OF MYELOMA CELLS WITH TAK-242 OVERCOMES BORTEZOMIB RESISTANCE
32. IN MULTIPLE MYELOMA THERE ARE TWO SUBSETS OF IMMUNOSUPPRESSIVE POLYMORPHONUCLEAR NEUTROPHILS WITH INCREASED LEVELS OF ARGINASE
33. POLYCLONAL SERUM IGM AS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA
34. Heme oxygenase 1 (HO-1) protects myeloma cells against bortezomib through nuclear translocation and regulation of ER stress and autophagy proteins
35. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
36. SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS
37. GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS (MSC)
38. UP-REGULATION OF PROK-2/BV8 IN GRANULOCYTES IS PRESENT BOTH IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA
39. NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS
40. ACINETOBACTER BAUMANNII SURVEILLANCE MEASURES IN HAEMATOLOGICAL MALIGNANCIES PATIENTS
41. HS-TROPONINE T RELATES WITH MYOCARDIAL IRON OVERLOAD IN TRANSFUSION DEPENDENT THALASSEMIC PATIENTS
42. OVEREXPRESSION OF ARGINASE AND PROK-2 MAKES NEUTROPHILS OF MULTIPLE MYELOMA DYSFUNCTIONAL AND IMMUNOSUPPRESSIVE
43. BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION
44. Role of nuclear heme oxygenase 1 in bortezomib induced cell death and genomic instability of multiple myeloma cells 100:157. 45th Congress of the Italian-Society-of-Hematology, Florence, ITALY, OCT 04-07, 2015
45. Oral Lesion as Unusual First Manifestation of Multiple Myeloma: Case Reports and Review of the Literature
46. Troponine T as a marker of cardiac impairment in patients suffering thalassemia
47. Bortezomib induced expression of heme oxygenase 1 via endoplasmic reticulum stress 19th Congress of the European-Hematology-Association. Milan, ITALY. Jun 12-15, 2014
48. SUBCUTANEOUS VELCADE PLUS PREDNISONE (VP) OR PLUS CYCLOPHOSFAMIDE (VCP) OR PLUS MELPHALAN (VMP) IN FRAIL, ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A PHASE II COMMUNITY–BASED STUDY
49. Efficacy and safety of 3 lenalidomide–based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based EMN01 trial
50. Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.